The aminoglycosides market focuses on a class of antibiotics used to treat severe bacterial infections, particularly those caused by Gram-negative bacteria. Common aminoglycosides include gentamicin, amikacin, tobramycin, and streptomycin, which are often administered intravenously or intramuscularly in hospital settings. These antibiotics work by inhibiting bacterial protein synthesis, making them highly effective against resistant infections and life-threatening conditions like sepsis, respiratory infections, and urinary tract infections. North America currently dominates the aminoglycosides market due to strong healthcare infrastructure and advanced antibiotic stewardship programs. However, Asia-Pacific is emerging as a high-growth region, fueled by a large patient base, increasing antibiotic usage, and growing awareness of infection control. Despite challenges such as nephrotoxicity concerns and antibiotic resistance, the aminoglycosides market remains a vital segment in the global fight against infectious diseases.
According to Fortune Business Insights, the aminoglycosides market share was valued at USD 1.87 billion in 2024 and is projected to grow from USD 1.92 billion in 2025 to USD 2.35 billion by 2032, exhibiting a CAGR of 2.95% during the forecast period. North America dominated the market, accounting for a 41.17% share in 2024.
The aminoglycosides market report covers detailed insights on market value, growth drivers, restraints, opportunities, and competitive dynamics. It provides data from 2019 to 2023 as historical analysis, 2024 as the base year, and projections through 2032. The report highlights trends across applications, routes of administration, product generations, and regional markets.
These companies are investing in the development of generic formulations, sterile injectables, and ophthalmic antibiotic products to expand their market share. In April 2025, Nordic Pharma, a subsidiary of Nordic Group B.V., announced the launch of a generic version of Maxitrol (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension), expanding treatment options for eye infections.